GlassScriptPhysician profile
Bradley Edgington
NPI 1366588295
$11,831.48
in general payments reported to CMS, 2019-2025
25 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2021: $21.09 · 2022: $9,847 · 2023: $278 · 2024: $854 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.91 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,846.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $327.43 | 2023-2025 | Bevespi Aerosphere, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $316.32 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $160.73 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.79 | 2023-2025 | Ofev, Spiriva Respimat |
| Grifols USA, LLC | $135.14 | 2024-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $128.40 | 2024-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $124.25 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $118.63 | 2019 | |
| Mylan Specialty L.P. | $57.95 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $55.82 | 2025 | Glassia |
| Viatris Specialty LLC | $53.58 | 2025 | Yupelri |
| Inogen, INC. | $42.76 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Abbvie INC. | $41.24 | 2025 | |
| United Therapeutics Corporation | $38.09 | 2021-2023 | Tyvaso |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $35.12 | 2024-2025 | Purified Cortrophin Gel |
| Insmed, INC. | $28.08 | 2024 | Arikayce |
| Philips North America LLC | $26.22 | 2024 | (Ak6) Vest Therapy |
| Ambu INC. | $23.70 | 2024 | |
| Electromed, INC. | $22.81 | 2024 | Smartvest |
| Pulmonx Corporation | $22.27 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $20.13 | 2025 | Zerbaxa |
| Amgen INC. | $18.37 | 2024 | Tezspire |
| Vifor Pharma, INC. | $15.63 | 2025 | Zemaira |
| Verona Pharma, INC. | $15.16 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Edgington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.